The ALKBH4 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma epithelial cells with targeted disruption of the ALKBH4 gene. This knockout model enables loss-of-function studies of ALKBH4, a dioxygenase that demethylates actin at residue K84me2, thereby regulating actin filament dynamics, cell motility, and cytokinesis. The polyclonal format offers a heterogeneous knockout pool that reflects the genetic diversity generated by CRISPR/Cas9-mediated gene editing without single-cell clonal isolation.
The parental A-549 cell line is a well-characterized adherent epithelial model originally derived from the lung adenocarcinoma tissue of a 58-year-old Caucasian male. A-549 cells are widely employed in cancer biology, drug discovery, and infectious disease research due to their stable growth characteristics, expression of lung adenocarcinoma markers, and susceptibility to adenovirus infection. This host cell background provides a physiologically relevant context for investigating genes involved in lung cancer progression and host?Cpathogen interactions.
ALKBH4 functions as a key regulator of the actin cytoskeleton by removing dimethyl marks from actin K84 (K84me2), promoting actin polymerization dynamics necessary for cell migration and cytokinesis. Its activity is negatively controlled by mTORC1-mediated phosphorylation, establishing a direct link between nutrient-sensing pathways and cytoskeletal remodeling. ALKBH4 interacts with actin and mTORC1, and its signaling network involves upstream growth factors, the mTORC1 kinase, and downstream effectors such as RAC1 and Rho GTPases that orchestrate actin-based processes.
In the context of A-549 lung adenocarcinoma cells, ALKBH4 knockout provides a powerful tool to dissect the contribution of actin demethylation to cancer cell migration, invasion, and metastatic potential. Given that A-549 cells are a standard model for adenovirus replication, and ALKBH4 has been implicated in modulating adenovirus replication, this knockout model also enables the study of how ALKBH4-dependent actin dynamics influence viral life cycles. Disruption of ALKBH4 in this model may reveal altered cytoskeletal organization and impaired cell division, offering insights into therapeutic targets for lung cancer and viral infections.
Researchers can employ this polyclonal ALKBH4 knockout cell population in a wide range of functional assays, including wound healing and Transwell migration/invasion assays to assess cell motility, immunofluorescence and phalloidin staining to visualize actin cytoskeleton alterations, and cytokinesis assays to evaluate cell division defects. Western blotting and RT-qPCR can confirm ALKBH4 loss and phospho-mTOR levels, while viral replication assays probe adenovirus propagation. This product is suited for target validation, pathway analysis, and drug screening. For additional information or to discuss custom projects, please contact Ascent Research.
